Zydus Lifesciences gets USFDA's nod to market generic version of Bortezomib
Zydus Lifesciences Ltd announced on Tuesday that the US Food and Drug Administration (USFDA) has given final approval to commercialize its generic version of Bortezomib for injection.
The USFDA has approved a single-dose vial of Bortezomib for injection with a strength of 3.5 mg per vial, according to a regulatory filing by the company. Pic: Reuters